Santen eyes uveitis market with top-line sirolimus data
This article was originally published in Scrip
Executive Summary
Japanese eye company Santen has released positive top-line data for the first Phase III trial of its sirolimus-based uveitis treatment.
You may also be interested in...
Keeping Track: So. Much. News.
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Breakthroughs Dominate 2017 Novel Agents; US FDA Approves Rydapt, Alunbrig, Tymlos, Brineura
The latest drug development news and highlights from our FDA Performance Tracker.
Oncology’s Hold Over The Pharma Pipeline Increases As Growth Slows
The rate of growth of the pharma pipeline slowed last year as oncology and rare diseases tightened their grip on R&D. There are also further signs of China’s rise in importance in the industry.